Fig. 3
Inhibiting PAD2 re-sensitizes MCF7/TamR cells to docetaxel. a MCF7/TamR cells were treated with cl-amidine at the indicated concentration for 4 days. CCK8 assay showing that 200 μM cl-amidine started to inhibit MCF7/TamR cell proliferation (***P < 0.001). b MCF7/TamR cells were treated with cl-amidine at the indicated concentration for 4 days. CCK8 assay showing that 50 μM cl-amidine combined with 5 μM tamoxifen significantly inhibited MCF7/TamR cell growth (*P < 0.05). c MCF7/TamR cells were treated with docetaxel at the indicated concentration for 4 days. CCK8 assay showing that at least 80 μM of docetaxel decreased MCF7/TamR cell viability (*P < 0.05). d MCF7/TamR cells were treated with 0.1 μM combined with different concentration of docetaxel for 4 days. CCK8 assay showing that at least 0.1 μM docetaxel and 25 μM cl-amidine combination significantly decreased MCF7/TamR cell viability (***P < 0.001). e MCF7/TamR cells were treated with 0.1 μM docetaxel and 25 μM cl-amidine for 1, 2, 3, 4, and 5 days. CCK8 assay showing that this combination completely inhibited MCF7/TamR cell viability (***P < 0.001)